Somatropin Market, By Dosage Form (Powder and Solvent), By Application (Growth Hormone Deficiency (GHD), Turner Syndrome, Chronic Renal Insufficiency, Prader Willi Syndrome, Small for Gestational Age, SHOX Deficiency, and Others), By Distribution Channel

Somatropin Market, By Dosage Form (Powder and Solvent), By Application (Growth Hormone Deficiency (GHD), Turner Syndrome, Chronic Renal Insufficiency, Prader Willi Syndrome, Small for Gestational Age, SHOX Deficiency, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

The increasing prevalence of growth hormone deficiency due to traumatic brain injuries is expected to propel the growth of the global somatropin market during the forecast period. According to an article published in the International Journal of Molecular Sciences in July 2021, growth hormone deficiency is the most common hormone deficiency in long term survivors of traumatic brain injury.
Market Dynamics
Market players are focusing on adopting various inorganic growth strategies such as agreements and acquisitions to strengthen their market presence and enhance their product portfolio. This is expected to drive growth of the global somatropin market during the forecast period. For instance, in October 2017, Ferring Pharmaceuticals entered a definitive agreement with Antares Pharma, Inc. to acquire the rights for the ZomaJet needle-free auto injector device.
Furthermore, research and development activities by key players are expected to propel the growth of global somatropin market during the forecast period. For instance, March 2017, GeneScience Pharmaceuticals Co., Ltd. initiated a phase 4 clinical trial to evaluate the safety and efficacy of PEG-Somatropin for the treatment of pediatric patients with growth hormone deficiency.
Key features of the study:
This report provides in-depth analysis of the global somatropin market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global somatropin market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, GeneScience Pharmaceuticals, Sandoz International, Ipsen Inc., LG Life Sciences, Merck KGaA, F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., and Ferring Pharmaceuticals
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, market expansion, and marketing tactics
The global somatropin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global somatropin market.
Detailed Segmentation:
Global Somatropin Market, By Dosage Form:
Powder
Solvent
Global Somatropin Market, By Application:
Growth Hormone Deficiency (GHD)
Turner Syndrome
Chronic Renal Insufficiency
Prader Willi Syndrome
Small for Gestational Age
SHOX Deficiency
Others
Global Somatropin Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Somatropin Market, By Region:
North America
By Dosage Form:
Powder
Solvent
By Application
Growth Hormone Deficiency (GHD)
Turner Syndrome
Chronic Renal Insufficiency
Prader Willi Syndrome
Small for Gestational Age
SHOX Deficiency
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Dosage Form:
Powder
Solvent
By Application
Growth Hormone Deficiency (GHD)
Turner Syndrome
Chronic Renal Insufficiency
Prader Willi Syndrome
Small for Gestational Age
SHOX Deficiency
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Dosage Form:
Powder
Solvent
By Application
Growth Hormone Deficiency (GHD)
Turner Syndrome
Chronic Renal Insufficiency
Prader Willi Syndrome
Small for Gestational Age
SHOX Deficiency
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Dosage Form:
Powder
Solvent
By Application
Growth Hormone Deficiency (GHD)
Turner Syndrome
Chronic Renal Insufficiency
Prader Willi Syndrome
Small for Gestational Age
SHOX Deficiency
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Dosage Form:
Powder
Solvent
By Application
Growth Hormone Deficiency (GHD)
Turner Syndrome
Chronic Renal Insufficiency
Prader Willi Syndrome
Small for Gestational Age
SHOX Deficiency
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Dosage Form:
Powder
Solvent
By Application
Growth Hormone Deficiency (GHD)
Turner Syndrome
Chronic Renal Insufficiency
Prader Willi Syndrome
Small for Gestational Age
SHOX Deficiency
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Novo Nordisk A/S*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Pfizer, Inc.
Eli Lilly and Company
GeneScience Pharmaceuticals
Sandoz International
Ipsen Inc.
LG Life Sciences
Merck KGaA
F. Hoffmann-La Roche
Teva Pharmaceutical Industries Ltd.
Ferring Pharmaceuticals
“*” marked represents similar segmentation in other categories in the respective section.